Panu M Jaakkola

6PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 01, 2026
Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma.

|Jul 23, 2025
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.

Anna Brännbäck, Ivan Mustonen, Teemu D Laajala

|Feb 24, 2024
Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study.

Saana Virtanen, Heidi Pihlman, Maria Silvoniemi

|Jan 11, 2022
Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.

Kalle E Mattila, Paula Vainio, Panu M Jaakkola

|Jun 03, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.

Reetta Virtakoivu, Jenna H Rannikko, Miro Viitala

|Jan 09, 2019
Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma.

Petra Miikkulainen, Heidi Högel, Fatemeh Seyednasrollah

Pageof 1

Frequent Collaborators

3 joint publications

Kalle E Mattila

1 joint publications

Reetta Virtakoivu

1 joint publications

Jenna H Rannikko

1 joint publications

Felix Vaura